Key Takeaways

Kisspeptin-10 is best understood as a potent research probe of reproductive neuroendocrine signaling, not as an established consumer hormone therapy.
It can acutely stimulate the upstream pathway that controls LH and FSH, but the published and regulatory record does not support broad claims that compounded kisspeptin-10 treats hypogonadism, preserves fertility during testosterone therapy, improves pregnancy rates, treats low sexual desire, or produces weight loss.
The safest summary is: biologically active, clinically interesting, and still investigational.

‍

[FDA, 2024; George et al., 2011; Jayasena et al., 2015].

‍

Kisspeptin-10: an unapproved, investigational synthetic decapeptide corresponding to the conserved C-terminal active sequence of human kisspeptin — H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 — that activates KISS1R/GPR54 upstream of gonadotropin-releasing hormone but remains in FDA's active 503A Category 2 safety-risk category.

Overview

Kisspeptin-10 occupies an unusually complicated evidence position. Unlike many wellness-market peptides, it has a real and repeatedly demonstrated human pharmacodynamic effect: acute intravenous administration can stimulate the hypothalamic-pituitary-gonadal axis, producing measurable changes in luteinizing hormone and, in some settings, follicle-stimulating hormone or testosterone. But the same-molecule human evidence is mainly a collection of small, short endocrine-provocation studies designed to interrogate physiology, not to establish a chronic treatment for hypogonadism, infertility, low libido, weight loss, or broad "hormone optimization." [George et al., 2011; Jayasena et al., 2011; FDA, 2024]

The central issue is therefore not absence of biology; it is evidence transfer. Kisspeptin-10 is often blended rhetorically with endogenous kisspeptin physiology, the longer peptide kisspeptin-54, long-acting KISS1R agonist analogues, and clinic-specific subcutaneous, intramuscular, buccal, troche, or intranasal protocols. Those materials are not interchangeable. A brief intravenous kisspeptin-10 challenge in five men with type 2 diabetes and low testosterone does not validate chronic subcutaneous treatment. Kisspeptin-54 studies in IVF or hypoactive sexual desire disorder do not establish efficacy for kisspeptin-10. And an acute LH rise is not the same endpoint as sustained testosterone normalization, spermatogenesis, pregnancy, sexual-function improvement, or weight loss. [George et al., 2013; Thurston et al., 2022; Mills et al., 2023; FDA, 2024]

The FDA evaluated kisspeptin-10 for secondary hypogonadism in men at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting. The committee voted 0 yes, 11 no, and 0 abstentions on inclusion in the 503A Bulks List, citing the lack of convincing safety and efficacy data. As of FDA's May 14, 2026 category update, kisspeptin-10 remains in active 503A Category 2, the category for bulk drug substances that raise significant safety risks. FDA specifically flags potential immunogenicity, peptide-related impurities, API-characterization complexity, and absent or limited route-specific safety information. [FDA, 2024; FDA, 2026; Federal Register, 2024]

What it is

Kisspeptin-10, often abbreviated KP-10 or Kp-10, is the amidated 10-amino-acid C-terminal fragment shared by the active human kisspeptin peptides. FDA identifies the sequence as H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. PubChem lists the molecular formula as C63H83N17O14 and a molecular weight of approximately 1302.4 g/mol. [FDA, 2024; PubChem, 2026; NCATS Inxight Drugs, 2025]

The endogenous biology begins upstream with the KISS1 gene. The human precursor is processed into several related peptides, commonly described as kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10. All share the C-terminal decapeptide required for receptor activation, but they differ in length, pharmacokinetics, tissue handling, and the clinical programs in which they have been studied. Kisspeptin-54, historically called metastin, is not simply a longer label for kisspeptin-10. [Kotani et al., 2001; Clarke et al., 2015; FDA, 2024]

The evidence boundary is strict. Human studies of intravenous kisspeptin-10 belong to this molecule and route. Human studies of kisspeptin-54, including much of the IVF, oocyte-maturation, and psychosexual literature, do not. Trials of long-acting KISS1R agonists such as TAK-448, TAK-683, or MVT-602/RVT-602 are analogue-specific. [Jayasena et al., 2015; ClinicalTrials.gov, 2026; Thurston et al., 2022; Mills et al., 2023]

Material	What it is	Why it cannot be collapsed into "Kisspeptin-10"
KISS1 precursor	Endogenous human precursor encoded by KISS1 and processed into multiple kisspeptins.	Gene expression and precursor physiology do not validate an exogenous drug product.
Kisspeptin-54 / metastin	Longer endogenous peptide containing the same active C-terminal decapeptide.	Different length and exposure profile; much of the IVF and sexual-brain-processing literature used KP-54, not KP-10.
Kisspeptin-14 / -13	Other endogenous cleavage products sharing the active C-terminus.	Related receptor agonists are not automatically route-, PK-, or efficacy-equivalent.
Synthetic native KP-10	Lab-manufactured amidated decapeptide with the native sequence.	This is the target molecule; evidence must still match route, formulation, population, schedule, and endpoint.
Long-acting KISS1R agonists	Engineered analogues such as TAK-448, TAK-683, or MVT-602/RVT-602 intended to alter potency or duration.	Analogue pharmacology and trial outcomes cannot be transferred to native KP-10.
Gray-market vial or troche	Clinic, compounding, or research-chemical presentation sold as injectable powder, solution, or buccal product.	Identity, sterility, potency, impurity profile, stability, route, and clinical dosing are not validated by the product name.

How it's proposed to work

The most defensible mechanistic anchor is receptor-level reproductive neuroendocrine signaling. Kisspeptin-10 is an agonist at KISS1R, historically called GPR54. Receptor activation in the hypothalamic reproductive network stimulates gonadotropin-releasing hormone output, which then acts on the pituitary to release LH and FSH. Those gonadotropins regulate gonadal steroidogenesis and gametogenesis. [Kotani et al., 2001; Skorupskaite et al., 2014; Clarke et al., 2015]

Human kisspeptin-10 studies confirm that the pathway is pharmacologically accessible, but the response is conditional rather than uniform. Acute intravenous bolus or infusion studies in healthy men reported LH stimulation and changes in pulse frequency; studies in women showed marked dependence on menstrual-cycle phase and sex-steroid feedback. Patients with idiopathic hypogonadotropic hypogonadism can be responsive, unresponsive, or responsive only in specific genetic or recovery states. [George et al., 2011; Jayasena et al., 2011; George et al., 2012; Chan et al., 2014; Lippincott et al., 2016]

Exposure pattern is another load-bearing feature. FDA calculated an intravenous plasma half-life of approximately four minutes in men and women. In healthy men, a low-dose continuous infusion lasting about 22.5 hours did not show the same desensitization seen in some higher-exposure animal experiments. By contrast, continuous kisspeptin-10 exposure in juvenile male rhesus monkeys produced KISS1R desensitization. [George et al., 2011; Seminara et al., 2006; FDA, 2024]

The mechanism map also extends beyond the hypothalamus. KISS1/KISS1R signaling appears in placental trophoblast biology, vascular and cardiac systems, and other peripheral tissues. Kisspeptin-10 inhibited trophoblast invasion in a foundational cell study, and later preclinical work raised context-dependent vascular, atherosclerotic, and myocardial-fibrosis questions. [Bilban et al., 2004; Sato et al., 2017; Radwańska et al., 2023; FDA, 2024]

Common forms in circulation

FDA evaluated a nomination for 1 mg/mL kisspeptin-10 solutions for subcutaneous and intramuscular injection in the context of secondary hypogonadism in men. FDA found no applicable USP/NF monograph and stated that kisspeptin-10 is not a component of an FDA-approved drug. [FDA, 2024; FDA, 2026]

FDA's 2024 market scan found injectable products described at 100 or 200 micrograms/mL, a 200-microgram troche, and 10-mg research products. Current peptide sellers continue to list 10-mg lyophilized vials, while clinic pages frame kisspeptin therapy around fertility, libido, testosterone support, "hormone balance," and weight-related goals. [FDA, 2024; Core Peptides, 2026; LIVV Natural, 2025; Dr. Shel Wellness, 2026]

The strongest same-molecule human evidence is intravenous. FDA found only one study using a single subcutaneous bolus in approximately 35 healthy women, with safety outcomes not reported, and no human intramuscular studies. A buccal troche, at-home subcutaneous injection, or intramuscular protocol therefore cannot inherit the certainty of a controlled intravenous endocrine study. [Jayasena et al., 2011; FDA, 2024]

Names and aliases

Scientific and database names include Kisspeptin-10, kisspeptin 10, KP-10, Kp-10, metastin 45-54, human metastin 45-54, kisspeptin 112-121, and KISS1-derived decapeptide. "Metastin" without a residue range often refers to kisspeptin-54 and should not be assumed to mean kisspeptin-10. [FDA, 2024; NCATS Inxight Drugs, 2025; PubChem, 2026]

Market pairings to flag include kisspeptin-10 with testosterone replacement therapy, hCG, hMG, gonadorelin, clomiphene, enclomiphene, aromatase inhibitors, PT-141, oxytocin, and other sexual-wellness or post-cycle-therapy programs. The "hCG alternative" frame is especially prominent in men's-health and peptide content. These pairings are protocol fashion and market positioning unless a controlled combination trial establishes a specific effect. [Red Fox Peptides, 2026; Houston Men's Clinic, 2023]

Regulatory status

Kisspeptin-10 has no FDA-approved indication. FDA states that it is not a component of an FDA-approved drug and that there is no applicable USP/NF drug-substance monograph. Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Clinic availability, prescriber involvement, or a pharmacy label therefore does not convert kisspeptin-10 into an approved therapy. [FDA, 2024; FDA, 2026]

The current list status is active 503A Category 2. FDA's document, updated May 14, 2026, places kisspeptin-10 in the category for substances that raise significant safety risks. This is not a withdrawn-nomination posture, Category 1 interim permissive posture, or a neutral "under review" status. [FDA, 2026]

The Pharmacy Compounding Advisory Committee considered kisspeptin-10 on October 29, 2024, under public docket FDA-2024-N-4188. FDA evaluated the proposed use of treatment of secondary hypogonadism in men and the nomination's additional rationale of preserving spermatogenesis during testosterone therapy. The committee question asked whether kisspeptin-10 should be placed on the 503A Bulks List. The vote was Yes: 0; No: 11; Abstain: 0. The final minutes state that the committee unanimously agreed against inclusion because of the lack of convincing safety and efficacy data. [Federal Register, 2024; FDA, 2024; FDA, 2026]

Any claim that FDA "reviewed" kisspeptin-10 and thereby validated it reverses the meaning of the record. [FDA, 2024]

Safety

The human safety database is reassuring only in a narrow acute sense. FDA estimated that roughly 300 subjects may have received kisspeptin-10 across published studies, with possible overlap. No serious adverse events were reported in the short studies reviewed, but many studies were small, brief, and did not fully report adverse events. FDA found no published chronic fixed-schedule study extending beyond one day; the longest repeated-bolus exposure was 11 hours in one day, and the longest infusion was 24 hours. [FDA, 2024]

Immunogenicity remains a formal gap. FDA identified no study designed to assess anti-drug antibodies or clinical immune responses. Because the target is related to an endogenous peptide, a theoretical neutralizing response could affect both the administered product and endogenous signaling. [FDA, 2024; FDA, 2026]

Endocrine risk is also pattern-dependent. Excessive or poorly timed stimulation could produce unwanted gonadotropin or sex-steroid changes; repeated or continuous exposure could produce reduced responsiveness in some contexts. An ambiguous FAERS report described weight gain and increased estrone in a 17-year-old male after compounded subcutaneous use, but the report was insufficient to establish causality. It should be treated as a signal of uncertainty, not as proof of a specific adverse reaction. [FDA, 2024]

Nonclinical safety is incomplete. FDA discussed limited-duration toxicology, absence of genotoxicity, developmental/reproductive-toxicity, and carcinogenicity packages, and preclinical vascular findings whose human relevance is uncertain. [Terse et al., 2021; Sato et al., 2017; Radwańska et al., 2023; FDA, 2024]

Purported benefits, by evidence

Purported benefit	Evidence strength	What the evidence supports	What it does not support
Acute LH/FSH stimulation	Human pharmacology - same molecule, mainly IV	Small human studies show that IV KP-10 can acutely stimulate LH and, variably, FSH in healthy volunteers and selected endocrine populations.	A chronic treatment claim, route equivalence, or guaranteed response in hypogonadal patients. [George et al., 2011; Jayasena et al., 2011; FDA, 2024]
Testosterone increase	Small human proof-of-concept	Continuous IV KP-10 increased testosterone in healthy men; a four-man T2DM/low-testosterone study reported acute LH and testosterone responses.	"Restores natural testosterone," durable normalization, symptom benefit, or efficacy of SC/IM clinic protocols. [George et al., 2011; George et al., 2013; FDA, 2024]
Secondary hypogonadism treatment	Exploratory human physiology; insufficient therapeutic evidence	KP-10 has been used to probe GnRH neuronal function in IHH and other disorders, with heterogeneous responses.	"Treats hypogonadism," "replaces TRT," or established chronic efficacy. FDA found the evidence insufficient. [Young et al., 2013; Chan et al., 2014; Lippincott et al., 2016; FDA, 2024]
Male fertility / spermatogenesis	Mechanistic plausibility plus indirect human endocrine data	The pathway is upstream of gonadotropins that regulate spermatogenesis, making fertility research plausible.	Improved sperm count, preservation during TRT, pregnancy, or equivalence to hCG/hMG without direct clinical outcomes. [Skorupskaite et al., 2014; FDA, 2024]
Female ovulation / IVF / oocyte maturation	Human clinical research largely KP-54 or analogue-specific	The kisspeptin pathway is clinically relevant to ovulation and assisted reproduction, and KP-54/agonists have been studied for oocyte-maturation triggering.	Transferring IVF success, mature oocyte, pregnancy, or OHSS findings to KP-10 products. [Clarke et al., 2015; ClinicalTrials.gov, 2026]
Fertility preservation during TRT / "hCG alternative"	Commercial claim with mechanistic rationale	Clinics and peptide content market KP-10 as an upstream alternative or adjunct to hCG.	Clinical equivalence to hCG, prevention of testicular atrophy, preserved sperm production, or proven PCT efficacy. [FDA, 2024; Red Fox Peptides, 2026]
Libido / sexual desire / erectile response	Human randomized evidence for IV KP-54, not KP-10	Two small randomized studies in HSDD reported changes in sexual brain-processing and behavioral measures after IV kisspeptin-54.	"KP-10 treats low libido," "improves erections," or efficacy of clinic injection/troche protocols. [Thurston et al., 2022; Mills et al., 2023]
Weight loss / lipolysis / body composition	Commercial and mechanistic speculation	FDA documented clinic claims connecting kisspeptin to lipolysis, fat accumulation, and weight loss.	"Weight-loss peptide," clinically meaningful fat loss, metabolic treatment, or body-recomposition efficacy. [FDA, 2024]

Key literature

Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G-protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. Foundational identification of KISS1-derived peptides as natural GPR54/KISS1R ligands.

George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. Acute LH stimulation, pulse changes, and testosterone response in healthy men.

Jayasena CN, Nijher GMK, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963-E1972. Sex- and cycle-dependent endocrine response; approximately four-minute IV half-life.

Clarke H, Dhillo WS, Jayasena CN. Comprehensive review on kisspeptin and its role in reproductive disorders. Endocrinol Metab (Seoul). 2015;30(2):124-141. A broad review of kisspeptin biology and reproductive-disorder relevance.

Thurston L, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open. 2022;5(10):e2236131. KP-54 altered sexual/attraction brain processing and related measures.

Mills EG, Ertl N, Wall MB, et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder. JAMA Netw Open. 2023;6(2):e2254313. KP-54 psychosexual and penile-tumescence findings in 32 men.

References

U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document 5: Kisspeptin-10. 2024.
U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - Summary Minutes. 2024.
Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. September 18, 2024. Docket FDA-2024-N-4188.
PubChem. Kisspeptin-10. PubChem Compound Summary, CID 25240297. Accessed July 2026.
World Anti-Doping Agency. The 2026 Prohibited List. Effective January 1, 2026.

Kisspeptin-10